3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
7
Genitourinary
5
Thoracic
3
Gynecologic
2
Tumor-Agnostic
1
Other solid neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasm Metastasis
1
Interventions
Paclitaxel
26
Carboplatin
25
pembrolizumab
22
Gemcitabine
22
Nivolumab
20
Cisplatin
15
Bevacizumab
14
Docetaxel
13
Pemetrexed
12
Ipilimumab
12
Erlotinib Hydrochloride
12
Capecitabine
12
Fluorouracil
11
Irinotecan
10
Afatinib
10
eribulin
9
BI 6727
9
130-nm albumin-bound paclitaxel
9
Radiotherapy
8
Magnetic Resonance Spectroscopy
8
Leucovorin
8
Everolimus
8
Cyclophosphamide
8
Albumin-Bound Paclitaxel
8
olaparib
7
Oxaliplatin
7
lenvatinib
6
avelumab
6
Trastuzumab
6
Cetuximab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
sacituzumab govitecan
×
Tumor-Agnostic
×
Clear all
NCT03964727
2026-04-28
TROPiCS-03
Gilead Sciences
Phase 2
Active not recruiting
227 enrolled
31 charts